Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients

Clinical Lung Cancer

Volumn 4, Issue 4, 2003, Pages 237-241

  Camps, Carlos ^a   Sarries, Carmen ^b   Roig, Bárbara ^b   Sánchez, José Javier ^c   Queralt, Cristina ^b   Sancho, Eva ^a   Martinez, Natividad ^a   Tarón, Miguel ^b   Rosell, Rafael ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c University Hospital of Madrid   (Spain)

Author keywords

Chemotherapy resistance; Cockayne syndrome; DNA adducts; DNA repair; ERCC1; Transcription coupled repair; Xeroderma pigmentosum genes

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA DAMAGE; DNA ISOLATION; DNA POLYMORPHISM; DRUG RESPONSE; EXCISION REPAIR; FEMALE; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; RNA TRANSLATION;

EID: 0038207859     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.004     Document Type: Article

References (25)

1. Phillips DH. The formation of DNA adducts. In: Alison MR, ed. The Cancer Handbook. London, England: Nature Publishing Group; 2002:293-307.
2. Siddik ZH. Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: Alison MR, ed. The Cancer Handbook. London, England: Nature Publishing Group; 2002:1295-1313.
3. Hanawalt PC. Controlling the efficiency of excision repair. Mutat Res 2001; 485:3-13.
4. May A, Nairn RS, Okumoto DS, et al. Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J Biol Chem 1993; 268:1650-1657.
5. McKay BC, Ljungman M, Rainbow AJ. Persistent DNA damage induced by ultraviolet light inhibits p21 waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene 1998; 17:545-555.
6. Cullinane C, Mazur SJ, Essigmann JM, et al. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 1999; 38:6204-6212.
7. Conforti G, Nardo T, D'Incalci M, et al. Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation. Oncogene 2000; 19:2714-2720.
8. Takebayashi Y, Nakayama K, Kanzaki A, et al: Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett 2001; 174:115-125.
9. Rajewsky MF, Müller R. DNA repair and the cell cycle as targets in cancer therapy. In: Alison MR, ed. The Cancer Handbook. London, England: Nature Publishing Group 2002:1507-1519.
10. McKay BC, Becerril C, Ljungman M. p53 plays a protective role against Uv- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 2001; 20:6805-6808.
11. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62:4899-4902.
12. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-316.
13. Dabhulkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94:703-708.
14. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res 2002; 8:2286-2291.
15. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61:1354-1357.
16. Bosken CH, Wei Q, Amos CI, et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002; 94:1091-1099.
17. Zeng-Rong N, Paterson J, Alpert P, et al. Elevated DNA capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995; 55:4760-4764.
18. Wei Q, Cheng L, Ki Hong W, et al. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996; 56:4103-4107.
19. Wei Q, Cheng L, Amos CI et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92:1764-1772.
20. Cheng L, Sptiz MR, Hong WK, et al. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 2000; 21:1527-1530.
21. Cheng L, Guan Y, Li L, et al. Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 1999; 8:801-807.
22. Vogel U, Dybdahl M, Frentz G, et al. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 2000; 461:197-210.
23. Cheng L, Sturgis EM, Eicher SA, et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002; 94:393-397.
24. Park DJ, Stoehlmacher J, Zhang W, et al. A xeroderma pigmentosum group D gene polymorphisin predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61:8654-8658.
25. Aloyz R, Xu ZY, Bello V, et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 2002; 62:5457-5462.